<DOC>
	<DOCNO>NCT00906061</DOCNO>
	<brief_summary>There little information Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 2 patient analyzed clinical trial . The rate patient recruit Treatment Chemotherapy 1st Line Advanced NSCLC clinical trial le 20 percent . This low rate make investigator think possibility bias selection , due existence exclusion criterion permit include patient deteriorate performance status . In types patient , toxicity important issue decide therapeutic strategy . Gemcitabine Docetaxel combination interest different toxicity profile . This combination demonstrate activity several type tumour , breast cancer , sarcoma lung cancer . The strategy perform study biweekly combination Gemcitabine Docetaxel ; activity dose intensity , toxicity significantly low .</brief_summary>
	<brief_title>Biweekly Gemcitabine Docetaxel First Line Therapy Advanced Non-Small Cell Lung Cancer ( NSCLC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advance NSCLC . Stage III pleural effusion stage IV . Patients ECOG PS 2 . Patients must least one measurable lesion , previously irradiate . Life expectancy least 12 week . Adequate organ function accord follow criterion : Bone marrow : ANC = &gt; 2.0x10 ( 9 ) cells/L ; Platelet count = &gt; 100x10 ( 9 ) cells/L ; Hemoglobin = &gt; 10 g/dL . Liver function : Bilirubin &lt; = 1.5 X ULN ; Alkaline phosphatase &lt; = 5 x ULN ; AST ALT &lt; = 1.5 x ULN . Renal function : serum creatinine &lt; = 2mg/dL . Prior systemic chemotherapy advance disease . Prior radiotherapy NSCLC . Patients symptomatic brain metastasis . No measurable bone metastasis malignant pleural effusion measurable lesion . History prior malignancy , except curatively treat situ carcinoma cervix cancer curatively treat evidence disease least five year . History hypersensitivity reaction study drug . Pregnant lactate woman ( woman childbearing potential must use adequate contraception ) . Concurrent treatment experimental drug . Current peripheral neuropathy NCI grade 2 . Participation clinical trial within 30 day study entry . Major surgery , open biopsy traumatic lesion 28 day study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Carcinoma , Small Cell</keyword>
	<keyword>Lung Neoplasms</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>ECOG 2</keyword>
</DOC>